Christopher Martell serves as Executive at Candel Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Christopher Martell has executed 6 insider transactions totaling $1.1M, demonstrating a bullish approach to their equity position. Their most recent transaction on Dec 9, 2022 involved purchasing 23,950 shares valued at $46.0K.
Christopher Martell currently holds 152,000 shares of Candel Therapeutics, Inc. (CADL), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Christopher Martell has been a net buyer of CADL stock. They have purchased $1.1M and sold $0 worth of shares.
Christopher Martell's most recent insider trade was on Dec 9, 2022, when they purchased 23,950 shares at $1.92 per share.
Get notified when new Form 4 filings are submitted
| $1.92 |
| Discretionary |
| Dec 8, 2022 | CADL | $5.1K | Purchase | 3,050 | $1.68 | Discretionary |
| Dec 8, 2022 | CADL | $5.1K | Purchase | 3,050 | $1.68 | Discretionary |
| Jul 29, 2021 | CADL | $1.0M | Purchase | 125,000 | $8.00 | Discretionary |
| Jul 29, 2021 | CADL | $0 | Conversion | 283,514 | $N/A | Discretionary |